-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DJhCc9s89lAHmN49VUg2gnUcqPkJpi93smODkqcqmBer5Y5xj7CubvW49dMbnZCm Fgw2yw2sr2AxcDeUvdBxDw== 0001104659-05-006341.txt : 20050214 0001104659-05-006341.hdr.sgml : 20050214 20050214152055 ACCESSION NUMBER: 0001104659-05-006341 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20050214 DATE AS OF CHANGE: 20050214 GROUP MEMBERS: ALAN G. WALTON GROUP MEMBERS: CORNELIUS T. RYAN GROUP MEMBERS: EDMUND M. OLIVIER GROUP MEMBERS: JONATHAN J. FLEMING GROUP MEMBERS: OBP MANAGEMENT (BERMUDA) II LIMITED PARTNERSHIP GROUP MEMBERS: OBP MANAGEMENT (BERMUDA) II LTD GROUP MEMBERS: OBP MANAGEMENT II, LP GROUP MEMBERS: OXFORD BIOSCIENCE PARTNERS (ADJUNCT) II, LP GROUP MEMBERS: OXFORD BIOSCIENCE PARTNERS (BERMUDA) II LIMITED PARTNERSHIP GROUP MEMBERS: OXFORD BIOSCIENCE PARTNERS (GS-ADJUNCT)II, LP GROUP MEMBERS: OXFORD BIOSCIENCE PARTNERS II (ANNEX) LP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MEMORY PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001062216 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-80464 FILM NUMBER: 05609071 BUSINESS ADDRESS: STREET 1: 100 PHILIPS PARKWAY CITY: MONTVALE STATE: NJ ZIP: 07645 BUSINESS PHONE: 2018027100 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: OXFORD BIOSCIENCE PARTNERS II L P CENTRAL INDEX KEY: 0001022420 IRS NUMBER: 061460505 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: C/O OXFORD BIOSCIENCE PARTNERS STREET 2: 315 POST ROAD WEST CITY: WESTPORT STATE: CT ZIP: 06880 BUSINESS PHONE: 2032413300 MAIL ADDRESS: STREET 1: OXFORD BIOSCIENCE PARTNERS STREET 2: 222 BERKELEY ST., SUITE 1650 CITY: BOSTON STATE: MA ZIP: 02116 SC 13G 1 a05-3330_1sc13g.htm SC 13G

 

 

UNITED STATES

OMB APPROVAL

 

SECURITIES AND EXCHANGE COMMISSION

OMB Number:
3235-0145

 

Washington, D.C. 20549

Expires:
December 31, 2005

 

SCHEDULE 13G

Estimated average burden hours per response. . 11.00

 

Under the Securities Exchange Act of 1934
(Amendment No.    )*

 

Memory Pharmaceuticals Corp.

(Name of Issuer)

 

Common Stock, $0.001 Par Value

(Title of Class of Securities)

 

58606R403

(CUSIP Number)

 

December 31, 2004

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o

Rule 13d-1(b)

o

Rule 13d-1(c)

ý

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 


 

 

CUSIP No.  58606R403

 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Oxford Bioscience Partners II L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0 Shares

 

6.

Shared Voting Power 
1,835,545 Shares

 

7.

Sole Dispositive Power 
0 Shares

 

8.

Shared Dispositive Power
1,835,545 Shares

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,835,545 Shares

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
8.97%

 

 

12.

Type of Reporting Person (See Instructions)
PN

 

2


 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Oxford Bioscience Partners (Adjunct) II L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0 Shares

 

6.

Shared Voting Power 
1,835,545 Shares

 

7.

Sole Dispositive Power 
0 Shares

 

8.

Shared Dispositive Power
1,835,545 Shares

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,835,545 Shares

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
8.97%

 

 

12.

Type of Reporting Person (See Instructions)
PN

 

3


 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Oxford Bioscience Partners (GS-Adjunct) II L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0 Shares

 

6.

Shared Voting Power 
1,835,545 Shares

 

7.

Sole Dispositive Power 
0 Shares

 

8.

Shared Dispositive Power
1,835,545 Shares

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,835,545 Shares

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
8.97%

 

 

12.

Type of Reporting Person (See Instructions)
PN

 

4


 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Oxford Bioscience Partners II (Annex) L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0 Shares

 

6.

Shared Voting Power 
1,835,545 Shares

 

7.

Sole Dispositive Power 
0 Shares

 

8.

Shared Dispositive Power
1,835,545 Shares

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,835,545 Shares

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
8.97%

 

 

12.

Type of Reporting Person (See Instructions)
PN

 

5


 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
OBP Management II L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0 Shares

 

6.

Shared Voting Power 
1,835,545 Shares

 

7.

Sole Dispositive Power 
0 Shares

 

8.

Shared Dispositive Power
1,835,545 Shares

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,835,545 Shares

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
8.97%

 

 

12.

Type of Reporting Person (See Instructions)
PN

 

6


 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Oxford Bioscience Partners (Bermuda) II Limited Partnership

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Bermuda

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0 Shares

 

6.

Shared Voting Power 
1,835,545 Shares

 

7.

Sole Dispositive Power 
0 Shares

 

8.

Shared Dispositive Power
1,835,545 Shares

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,835,545 Shares

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
8.97%

 

 

12.

Type of Reporting Person (See Instructions)
PN

 

7


 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
OBP Management (Bermuda) II Limited Partnership

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Bermuda

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0 Shares

 

6.

Shared Voting Power 
1,835,545 Shares

 

7.

Sole Dispositive Power 
0 Shares

 

8.

Shared Dispositive Power
1,835,545 Shares

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,835,545 Shares

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
8.97%

 

 

12.

Type of Reporting Person (See Instructions)
PN

 

8


 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
OBP Management (Bermuda) II Ltd.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Bermuda

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0 Shares

 

6.

Shared Voting Power 
1,835,545 Shares

 

7.

Sole Dispositive Power 
0 Shares

 

8.

Shared Dispositive Power
1,835,545 Shares

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,835,545 Shares

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
8.97%

 

 

12.

Type of Reporting Person (See Instructions)
CO

 

9


 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Edmund M. Olivier

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
United States

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0 Shares

 

6.

Shared Voting Power 
1,835,545 Shares

 

7.

Sole Dispositive Power 
0 Shares

 

8.

Shared Dispositive Power
1,835,545 Shares

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,835,545 Shares

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
8.97%

 

 

12.

Type of Reporting Person (See Instructions)
IN

 

10


 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Cornelius T. Ryan

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
United States

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0 Shares

 

6.

Shared Voting Power 
1,835,545 Shares

 

7.

Sole Dispositive Power 
0 Shares

 

8.

Shared Dispositive Power
1,835,545 Shares

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,835,545 Shares

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
8.97%

 

 

12.

Type of Reporting Person (See Instructions)
IN

 

11


 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Alan G. Walton

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
United States

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0 Shares

 

6.

Shared Voting Power 
1,835,545 Shares

 

7.

Sole Dispositive Power 
0 Shares

 

8.

Shared Dispositive Power
1,835,545 Shares

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,835,545 Shares

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
8.97%

 

 

12.

Type of Reporting Person (See Instructions)
IN

 

12


 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Jonathan J. Fleming

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
United States

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0 Shares

 

6.

Shared Voting Power 
1,835,545 Shares

 

7.

Sole Dispositive Power 
0 Shares

 

8.

Shared Dispositive Power
1,835,545 Shares

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,855,545 Shares

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
8.97%

 

 

12.

Type of Reporting Person (See Instructions)
IN

 

13


 

NOTE:  This Statement on Schedule 13G is being filed on behalf of: (i) Oxford Bioscience Partners II L.P., a Delaware limited partnership; (ii) Oxford Bioscience Partners (Adjunct) II L.P., a Delaware limited partnership; (iii) Oxford Bioscience Partners (GS-Adjunct) II L.P., a Delaware limited partnership; (iv) Oxford Bioscience Partners II (Annex) L.P., a Delaware limited partnership; (v) OBP Management II L.P., a Delaware limited partnership; (vi) Oxford Bioscience Partners (Bermuda) II Limited Partnership, a Bermuda limited partnership; (vii) OBP Management (Bermuda) II Limited Partnership, a Bermuda limited partnership; (viii) OBP Management (Bermuda) II Ltd., a Bermuda company; (ix) Edmund M. Olivier; (x) Cornelius T. Ryan; (xi) Alan G. Walton; and (xii) Jonathan J. Fleming.

Item 1.

 

(a)

Name of Issuer
Memory Pharmaceuticals Corp.

 

(b)

Address of Issuer’s Principal Executive Offices
100 Philips Parkway, Montvale, New Jersey 07645

Item 2.

(a)

 

(b)

 

(c)

Name of Person Filing

 

Address

 

Citizenship or Place of Organization

Oxford Bioscience Partners II L.P. (“OBP II”)

 

Oxford Bioscience Partners
315 Post Road West
Westport, CT 06880

 

Delaware

Oxford Bioscience Partners (Adjunct) II L.P. (“OBP Adjunct II”)

 

Oxford Bioscience Partners
315 Post Road West
Westport, CT 06880

 

Delaware

Oxford Bioscience Partners (GS-Adjunct) II L.P. (“OBP GS-Adjunct II”)

 

Oxford Bioscience Partners
315 Post Road West
Westport, CT 06880

 

Delaware

Oxford Bioscience Partners II (Annex) L.P. (“OBP Annex II”)

 

Oxford Bioscience Partners
315 Post Road West
Westport, CT 06880

 

Delaware

OBP Management II L.P. (“OBP Management II”) the general partner of OBP II, OBP Adjunct II, OBP GS-Adjunct II and OBP Annex II

 

Oxford Bioscience Partners
315 Post Road West
Westport, CT 06880

 

Delaware

Oxford Bioscience Partners (Bermuda) II Limited Partnership (“OBP Bermuda II”)

 

Richmond House
Par-la-Ville Road
Hamilton, Bermuda

 

Bermuda

OBP Management (Bermuda) II Limited Partnership (“OBP Management Bermuda II”), the general partner of OBP Bermuda II

 

Richmond House
Par-la-Ville Road
Hamilton, Bermuda

 

Bermuda

OBP Management (Bermuda) II Ltd. (“OBP Bermuda II Ltd.”), the corporate general partner of OBP Management Bermuda II

 

Richmond House
Par-la-Ville Road
Hamilton, Bermuda

 

Bermuda

Edmund M. Olivier, a general partner of OBP Management II and OBP Management Bermuda II

 

Oxford Bioscience Partners
650 Town Center Drive
Costa Mesa, California  92626

 

United States

Cornelius T. Ryan, a general partner of OBP Management II and OBP Management Bermuda II

 

Oxford Bioscience Partners
315 Post Road West
Westport, CT 06880

 

United States

Alan G. Walton, a general partner of OBP Management II and OBP Management Bermuda II

 

Oxford Bioscience Partners
315 Post Road West
Westport, CT 06880

 

United States

Jonathan J. Fleming, a general partner of OBP Management II and OBP Management Bermuda II

 

Oxford Bioscience Partners
222 Berkeley Street
Boston, MA 02116

 

United States

 

(d)

Title of Class of Securities
Common Stock, $0.001 par value.

 

(e)

CUSIP Number
58606R403

 

14


 

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)

o

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

(b)

o

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

(c)

o

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

(d)

o

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

 

(e)

o

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 

(f)

o

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

 

(g)

o

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

 

(h)

o

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

(i)

o

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

(j)

o

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

 

None of the above.

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a)

Amount beneficially owned:    
As of December 31, 2004, each of the following is the owner of record of the number of shares, or options to purchase the number of shares of Common Stock set forth next to his, her or its name:

 

 

 

OBP II:

357,715 Shares

 

 

 

 

OBP Adjunct II:

100,306 Shares

 

 

 

 

OBP GS-Adjunct II:

352,679 Shares

 

 

 

 

OBP Annex II:

757,001 Shares

 

 

 

 

OBP Management II:

0 Shares

 

 

 

 

OBP Bermuda II:

267,844 Shares

 

 

 

 

OBP Management Bermuda II:

0 Shares

 

 

 

 

OBP Bermuda II Ltd.:

0 Shares

 

 

 

 

Mr. Olivier:

0 Shares

 

 

 

 

Mr. Ryan:

0 Shares

 

 

 

 

Mr. Walton:

0 Shares

 

 

 

 

Mr. Fleming:

0 Shares

 

 

 

By virtue of their relationship as affiliated limited partnerships, whose sole general partners share individual general partners, OBP II, OBP Adjunct II, OBP GS-Adjunct II, OBP Annex II and OBP Bermuda II may be deemed to share voting power and the power to direct the disposition of the shares of Common Stock which each partnership owns of record.  OBP Management II (as the general partner of OBP II, OBP Adjunct II, OBP GS-Adjunct II and OBP Annex II) and OBP Management Bermuda II (as the general partner of OBP Bermuda II) may also be deemed to own beneficially the shares of OBP II, OBP Adjunct II, OBP GS-Adjunct II,  OBP Annex II and OBP Bermuda II.  OBP Bermuda II Ltd., as the corporate general partner of OBP Management Bermuda II, may also be deemed to own beneficially the shares of OBP II, OBP Adjunct II, OBP GS-Adjunct II, OBP Annex II and OBP Bermuda II.  Messrs. Ryan, Walton, Olivier and Fleming are general partners of both OBP Management II, the general partner of OBP II, OBP Adjunct II, OBP GS-Adjunct II and OBP Annex II, and OBP Management Bermuda II, the general partner of OBP Bermuda II.  Therefore, each of Messrs. Ryan, Walton, Olivier and Fleming, the general partners of OBP Management II and OBP Management Bermuda II, may be deemed to own beneficially the shares held by OBP II, OBP Adjunct II, OBP GS-Adjunct II, OBP Annex II and OBP Bermuda II.

 

(b)

Percent of class:   

 

 

 

OBP II:

8.97%

 

 

 

 

OBP Adjunct II:

8.97%

 

 

 

 

OBP GS-Adjunct II:

8.97%

 

 

 

 

OBP Annex II

8.97%

 

 

 

 

OBP Management II:

8.97%

 

 

 

 

OBP Bermuda II:

8.97%

 

 

 

 

OBP Management Bermuda II:

8.97%

 

 

 

 

OBP Bermuda II Ltd.:

8.97%

 

 

 

 

Mr. Olivier:

8.97%

 

 

 

 

Mr. Ryan:

8.97%

 

 

 

 

Mr. Walton:

8.97%

 

 

 

 

Mr. Fleming:

8.97%

 

 

 

The foregoing percentages are calculated based on the 20,447,911 shares of Common Stock reported to be outstanding as of November 15, 2004 in the Quarterly Report on Form 10-Q of Memory Pharmaceuticals Corp. for the quarter ended September 30, 2004, as adjusted pursuant to Rule 13d-3 (d)(1) of the Act.

 

15


 

 

(c)

Number of shares as to which the person has:

 

 

(i)

Sole power to vote or to direct the vote

 

 

 

OBP II:

0 Shares

 

 

 

 

OBP Adjunct II:

0 Shares

 

 

 

 

OBP GS-Adjunct II:

0 Shares

 

 

 

 

OBP Annex II

0 Shares

 

 

 

 

OBP Management II:

0 Shares

 

 

 

 

OBP Bermuda II:

0 Shares

 

 

 

 

OBP Management Bermuda II:

0 Shares

 

 

 

 

OBP Bermuda II Ltd.:

0 Shares

 

 

 

 

Mr. Olivier:

0 Shares

 

 

 

 

Mr. Ryan:

0 Shares

 

 

 

 

Mr. Walton:

0 Shares

 

 

 

 

Mr. Fleming:

0 Shares

 

 

 

(ii)

Shared power to vote or to direct the vote

 

 

 

OBP II:

1,835,545 Shares

 

 

 

 

OBP Adjunct II:

1,835,545 Shares

 

 

 

 

OBP GS-Adjunct II:

1,835,545 Shares

 

 

 

 

OBP Annex II

1,835,545 Shares

 

 

 

 

OBP Management II:

1,835,545 Shares

 

 

 

 

OBP Bermuda II:

1,835,545 Shares

 

 

 

 

OBP Management Bermuda II:

1,835,545 Shares

 

 

 

 

OBP Bermuda II Ltd.:

1,835,545 Shares

 

 

 

 

Mr. Olivier:

1,835,545 Shares

 

 

 

 

Mr. Ryan:

1,835,545 Shares

 

 

 

 

Mr. Walton:

1,835,545 Shares

 

 

 

 

Mr. Fleming:

1,835,545 Shares

 

 

 

(iii)

Sole power to dispose or to direct the disposition of

 

 

 

OBP II:

0 Shares

 

 

 

 

OBP Adjunct II:

0 Shares

 

 

 

 

OBP GS-Adjunct II:

0 Shares

 

 

 

 

OBP Annex II

0 Shares

 

 

 

 

OBP Management II:

0 Shares

 

 

 

 

OBP Bermuda II:

0 Shares

 

 

 

 

OBP Management Bermuda II:

0 Shares

 

 

 

 

OBP Bermuda II Ltd.:

0 Shares

 

 

 

 

Mr. Olivier:

0 Shares

 

 

 

 

Mr. Ryan:

0 Shares

 

 

 

 

Mr. Walton:

0 Shares

 

 

 

 

Mr. Fleming:

0 Shares

 

 

 

(iv)

Shared power to dispose or to direct the disposition of

 

 

 

OBP II:

1,835,545 Shares

 

 

 

 

OBP Adjunct II:

1,835,545 Shares

 

 

 

 

OBP GS-Adjunct II:

1,835,545 Shares

 

 

 

 

OBP Annex II

1,835,545 Shares

 

 

 

 

OBP Management II:

1,835,545 Shares

 

 

 

 

OBP Bermuda II:

1,835,545 Shares

 

 

 

 

OBP Management Bermuda II:

1,835,545 Shares

 

 

 

 

OBP Bermuda II Ltd.:

1,835,545 Shares

 

 

 

 

Mr. Olivier:

1,835,545 Shares

 

 

 

 

Mr. Ryan:

1,835,545 Shares

 

 

 

 

Mr. Walton:

1,835,545 Shares

 

 

 

 

Mr. Fleming:

1,835,545 Shares

 

 

 

Each of OBP II, OBP Adjunct II, OBP GS-Adjunct II, OBP Annex II, OBP Management II, OBP Bermuda II, OBP Management Bermuda II, OBP Bermuda II Ltd., Mr. Olivier, Mr. Ryan, Mr. Walton and Mr. Fleming expressly disclaims beneficial ownership of any shares of Common Stock of Memory Pharmaceuticals Corp., except any shares held directly of record.

 

16


 

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   o.

 

 

 

 

 

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

 

 

 

 

 

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

 

 

 

 

 

 

Item 8.

Identification and Classification of Members of the Group

Not applicable. OBP II, OBP Adjunct II, OBP GS-Adjunct II, OBP Annex II, OBP Management II, OBP Bermuda II, OBP Management Bermuda II, OBP Bermuda II Ltd., Mr. Olivier, Mr. Ryan, Mr. Walton and Mr. Fleming expressly disclaim membership in a “group” as defined in Rule 13d-1(b)(ii)(J) of the Act.

 

 

 

 

 

 

Item 9.

Notice of Dissolution of Group

Not applicable.

 

 

 

 

 

 

Item 10.

Certification

By signing below each of Oxford Bioscience Partners II L.P., Oxford Bioscience Partners (Adjunct) II L.P., Oxford Bioscience Partners (GS-Adjunct) II L.P., Oxford Bioscience Partners II (Annex) L.P., OBP Management II L.P., Oxford Bioscience Partners (Bermuda) II Limited Partnership, OBP Management (Bermuda) II Limited Partnership, OBP Management (Bermuda) II Ltd., Edmund M. Olivier, Cornelius T. Ryan, Alan G. Walton, and Jonathan J. Fleming certify that, to the best of its or his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

17


 

Signature

After reasonable inquiry and to the best of his, her or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.  We also hereby agree to file this statement jointly pursuant to the agreement set forth as Exhibit 1.

 

Dated:  February 14, 2005

 

 

 

 

OXFORD BIOSCIENCE PARTNERS II L.P.

 

 

 

By: OBP Management II L.P., its general
partner

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

OXFORD BIOSCIENCE PARTNERS
(ADJUNCT) II L.P.

 

 

 

By: OBP Management II L.P., its general
partner

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

 

 

OXFORD BIOSCIENCE PARTNERS
(GS - ADJUNCT) II L.P.

 

 

 

By: OBP Management II L.P., its general
partner

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

OXFORD BIOSCIENCE PARTNERS
II (ANNEX) L.P.

 

 

 

By: OBP Management II L.P., its general
partner

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

OBP MANAGEMENT II L.P.

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

18


 

 

OXFORD BIOSCIENCE PARTNERS
(BERMUDA) II LIMITED PARTNERSHIP

 

 

 

By: OBP Management (Bermuda) II Limited
Partnership, its general partner

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

OBP MANAGEMENT (BERMUDA) II
LIMITED PARTNERSHIP

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

OBP MANAGEMENT (BERMUDA) II LTD.

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

*

 

 

Edmund M. Olivier

 

 

 

/s/ Cornelius T. Ryan

 

 

Cornelius T. Ryan

 

 

 

/s/ Alan G. Walton

 

 

Alan G. Walton

 

 

 

/s/ Jonathan J. Fleming

 

 

Jonathan J. Fleming

 

 

*By:

/s/ Raymond Charest

 

 

 

Raymond Charest as Attorney-in-Fact

 

 

 

 

This Schedule 13G was executed by Raymond Charest pursuant to Powers of Attorney, filed with the Securities and Exchange Commission on February 12, 1999, which Powers of Attorney are incorporated herein by reference and copies of which are attached hereto as Exhibit 2.

 

19

 EX-1 2 a05-3330_1ex1.htm EX-1

Exhibit 1

 

AGREEMENT

 

Pursuant to Rule 13-d1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Memory Pharmaceuticals Corp.

 

 

Dated:  February 14, 2005

 

 

 

 

 

 

OXFORD BIOSCIENCE PARTNERS II L.P.

 

 

 

By: OBP Management II L.P., its general
partner

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

 

 

OXFORD BIOSCIENCE PARTNERS
(ADJUNCT) II L.P.

 

 

 

By: OBP Management II L.P., its general
partner

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

 

 

OXFORD BIOSCIENCE PARTNERS
(GS - ADJUNCT) II L.P.

 

 

 

By: OBP Management II L.P., its general
partner

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 


 

 

OXFORD BIOSCIENCE PARTNERS
II (ANNEX) L.P.

 

 

 

By: OBP Management II L.P., its general
partner

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

OBP MANAGEMENT II L.P.

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

OXFORD BIOSCIENCE PARTNERS
(BERMUDA) II LIMITED PARTNERSHIP

 

 

 

By: OBP Management (Bermuda) II Limited
Partnership, its general partner

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

 

 

OBP MANAGEMENT (BERMUDA) II
LIMITED PARTNERSHIP

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

 

 

OBP MANAGEMENT (BERMUDA) II LTD.

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

Jonathan J. Fleming

 

 

General Partner

 

 

 

 

 

*

 

 

Edmund M. Olivier

 

 

 

 

 

/s/ Cornelius T. Ryan

 

 

Cornelius T. Ryan

 


 

 

/s/ Alan G. Walton

 

 

Alan G. Walton

 

 

 

 

 

/s/ Jonathan J. Fleming

 

 

Jonathan J. Fleming

 

 

 

 

*By:

/s/ Raymond Charest

 

 

 

Raymond Charest as Attorney-in-Fact

 

 

 

 

This Schedule 13G was executed by Raymond Charest pursuant to Powers of Attorney, filed with the Securities and Exchange Commission on February 12, 1999, which Powers of Attorney are incorporated herein by reference and copies of which are attached hereto as Exhibit 2.

 


 

POWER OF ATTORNEY

 

KNOW ALL MEN BY THESE PRESENTS, that the person whose signature appears below hereby constitutes and appoints Raymond N. Charest, Jeffrey M. Held, and Amy B. Rensko, and any one of them acting singly, the true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the undersigned and in the undersigned’s name, place and stead, in any and all capacities (until revoked in writing) to sign any and all instruments, certificates and documents required to be executed on behalf of the undersigned as an individual or on behalf of the undersigned’s holding company, as the case may be, pursuant to sections 13 and 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the By-laws of the National Association of Securities Dealers, Inc. granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary fully to all intents and purposes as the undersigned might or could do in person thereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Notwithstanding the foregoing, this Power of Attorney shall expire automatically upon the cessation of the undersigned’s reporting obligations pursuant to sections 13 and 16 of the Exchange Act or on the date that each attorney-in-fact is no longer employed in their current capacities.

 

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 7th day of February, 1999.

 

 

 

OXFORD BIOSCIENCE PARTNERS L.P.

 

 

 

 

 

By: OBP Management L.P., its general partner

 

 

 

 

 

 

By:

/s/ Cornelius T. Ryan

 

 

 

 

Cornelius T. Ryan

 

 

 

General Partner

 

 

 

 

 

 

 

OXFORD BIOSCIENCE PARTNERS (BERMUDA) LIMITED PARTNERSHIP

 

 

 

 

 

By: OBP Management (Bermuda) Limited Partnership,

 

 

 

its general partner

 

 

 

 

 

 

 

By:

/s/ Cornelius T. Ryan

 

 

 

 

Cornelius T. Ryan

 

 

 

General Partner

 


 

 

OBP MANAGEMENT L.P.

 

 

 

 

 

 

By:

/s/ Cornelius T. Ryan

 

 

 

 

Cornelius T. Ryan

 

 

 

General Partner

 

 

 

 

 

 

 

OBP MANAGEMENT (BERMUDA) LTD.

 

 

 

 

 

 

By:

/s/ Edmund M. Olivier

 

 

 

 

Edmund M. Olivier

 

 

 

Director

 

 

 

 

 

 

 

OBP MANAGEMENT (BERMUDA) LIMITED PARTNERSHIP

 

 

 

 

 

 

By:

/s/ Cornelius T. Ryan

 

 

 

 

Cornelius T. Ryan

 

 

 

General Partner

 

 

 

 

 

 

 

OXFORD BIOSCIENCE PARTNERS (ADJUNCT), L.P.

 

 

 

 

 

By: OBP Management, L.P., its general partner

 

 

 

 

 

 

 

By:

/s/ Cornelius T. Ryan

 

 

 

 

Cornelius T. Ryan

 

 

 

General Partner

 

 

 

 

 

 

 

OXFORD BIOSCIENCE MANAGEMENT PARTNERS II

 

 

 

 

 

 

By:

/s/ Cornelius T. Ryan

 

 

 

 

Cornelius T. Ryan

 

 

 

General Partner

 

 

 

 

 

 

 

OXFORD BIOSCIENCE PARTNERS II L.P.

 

 

 

 

 

By: OBP Management II L.P., its general partner

 

 

 

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

 

Jonathan J. Fleming

 

 

 

General Partner

 


 

 

OXFORD BIOSCIENCE PARTNERS (BERMUDA) II LIMITED PARTNERSHIP

 

 

 

 

 

By: OBP Management (Bermuda) II Limited Partnership, its

 

 

general partner

 

 

 

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

 

Jonathan J. Fleming

 

 

 

General Partner

 

 

 

 

 

 

 

OBP MANAGEMENT II, L.P.

 

 

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

 

Jonathan J. Fleming

 

 

 

General Partner

 

 

 

 

 

 

 

OBP MANAGEMENT (BERMUDA) II LIMITED PARTNERSHIP

 

 

 

 

 

By: OBP Management (Bermuda) II Ltd., its general partner

 

 

 

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

 

Jonathan J. Fleming

 

 

 

Director

 

 

 

 

 

 

 

OXFORD BIOSCIENCE PARTNERS (ADJUNCT) II, L.P.

 

 

 

 

 

By: OBP Management II, L.P., its general partner

 

 

 

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

 

Jonathan J. Fleming

 

 

 

General Partner

 

 

 

 

 

 

 

OBP MANAGEMENT (BERMUDA) II LTD.

 

 

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

 

Jonathan J. Fleming

 

 

 

Director

 


 

 

OXFORD BIOSCIENCE PARTNERS (GS - ADJUNCT) II, L.P.

 

 

 

 

 

By: OBP Management II, L.P., its general partner

 

 

 

 

 

 

 

By:

/s/ Jonathan J. Fleming

 

 

 

 

Jonathan J. Fleming

 

 

 

General Partner

 

 

 

 

 

 

 

 

 

 

/s/

Cornelius T. Ryan

 

 

 

 

Cornelius T. Ryan

 

 

 

 

 

 

 

 

 

 

 

/s/

Alan G. Walton

 

 

 

 

Alan G. Walton

 

 

 

 

 

 

 

 

 

 

 

/s/

Edmund M. Olivier

 

 

 

 

Edmund M. Olivier

 

 

 

 

 

 

 

 

 

 

 

/s/

Jonathan J. Fleming

 

 

 

 

Jonathan J. Fleming

 

 

 -----END PRIVACY-ENHANCED MESSAGE-----